BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31927036)

  • 1. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
    Ma T; Liang Y; Li Y; Song X; Zhang N; Li X; Chen B; Zhao W; Wang L; Yang Q
    Cell Signal; 2020 Apr; 68():109536. PubMed ID: 31927036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer.
    Liang Y; Li Y; Song X; Zhang N; Sang Y; Zhang H; Liu Y; Chen B; Zhao W; Wang L; Guo R; Yu Z; Yang Q
    Cancer Biol Ther; 2018 Feb; 19(2):120-131. PubMed ID: 29293402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long Non-Coding RNA (lncRNA) 91H Confers Tamoxifen Resistance in ER+ Breast Cancer Cells through Inhibiting mTOR Signaling Pathway.
    Lv ZY; Mo QP; Tang HC; Zheng SS
    Ann Clin Lab Sci; 2022 Nov; 52(6):947-955. PubMed ID: 36564063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer.
    Kim YC; Kim CY; Oh JH; Kim MH
    Cells; 2021 Jun; 10(7):. PubMed ID: 34209871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer.
    Xue X; Yang YA; Zhang A; Fong KW; Kim J; Song B; Li S; Zhao JC; Yu J
    Oncogene; 2016 May; 35(21):2746-55. PubMed ID: 26364613
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Fang Z; Wang Y; Wang Z; Xu M; Ren S; Yang D; Hong M; Xie W
    Cancer Res; 2020 Oct; 80(20):4399-4413. PubMed ID: 32826278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer.
    Peng WX; Huang JG; Yang L; Gong AH; Mo YY
    Mol Cancer; 2017 Oct; 16(1):161. PubMed ID: 29041978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
    Wu C; Luo J
    Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.
    Liu H; Wang G; Yang L; Qu J; Yang Z; Zhou X
    PLoS One; 2016; 11(12):e0168406. PubMed ID: 27977766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen.
    Wang S; Somisetty VS; Bai B; Chernukhin I; Niskanen H; Kaikkonen MU; Bellet M; Carroll JS; Hurtado A
    Oncogene; 2020 Oct; 39(40):6300-6312. PubMed ID: 32843722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
    Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
    Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Suppression of long non-coding RNA CCAT2 improves tamoxifen-resistant breast cancer cells' response to tamoxifen].
    Cai Y; He J; Zhang D
    Mol Biol (Mosk); 2016; 50(5):821-827. PubMed ID: 27830684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
    Wen J; Li R; Lu Y; Shupnik MA
    Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α-positive breast cancer cells.
    Jin ML; Kim YW; Jin HL; Kang H; Lee EK; Stallcup MR; Jeong KW
    Int J Cancer; 2018 Dec; 143(11):2871-2883. PubMed ID: 30191958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.
    Wang J; Xie S; Yang J; Xiong H; Jia Y; Zhou Y; Chen Y; Ying X; Chen C; Ye C; Wang L; Zhou J
    J Hematol Oncol; 2019 Jul; 12(1):81. PubMed ID: 31340867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer.
    Li Y; Jiang B; Zhu H; Qu X; Zhao L; Tan Y; Jiang Y; Liao M; Wu X
    Tumour Biol; 2017 Jun; 39(6):1010428317705790. PubMed ID: 28635401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
    Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
    Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
    Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA
    Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.